Could early signals have hinted at trouble for Aileron Therapeutics?
STAT Trials Pulse surfaced signals that Aileron's trial may have been struggling for significance more than a year before the company announced results that echoed these warnings — an announcement that led to a 41% drop in their stock. Staying on top of red flags in critical drug pipelines can aid investors in getting ahead of market-moving announcements and allow biopharma professionals to strategize ahead of time. With STAT Trials Pulse, you can detect red flags before they become public knowledge.
Book a demo
In mid-May 2021, a group of irregularities detected by STAT Trials Pulse surfaced red flags in the ALRN-6924 trial, serving as an early warning of potential problems. More than a year later, Aileron announced the disappointing results of an interim analysis, highlighting that ALRN-6924 was not performing better than placebo and that it planned to stop further enrollment.
To get early signals like this about the companies, drugs, and diseases you want to monitor, book a demo today.
No comments